Advanced Enzyme Technologies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹203Cr
- +21.6% YoY
- +18% QoQ
- Net profit
- ₹45Cr
- +66.7% YoY
- +4.7% QoQ
- Margin
- 31%
- +4 pp YoY
- +2 pp QoQ
Guidance rank: #81 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
2 of 4 strong
The short version
The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.
From Advanced Enzyme Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. (Page 13, 14)
- Moderate growth is anticipated from emerging areas like biocatalysis and new products under trial, with some launches expected this year. (Page 13)
- U.S. business is under pressure with a challenging market environment, but the company is working on regulatory registrations and increasing market share for future growth. (Pages 20, 8)
- Indian business showed strong growth, expected to continue, fueled by volume growth and some potential price increases. (Pages 8, 9)
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.
- Overall R&D CapEx is expected to be around INR 130 crores, including INR 50 million increase in R&D revenue expenditure.
- Infrastructure buildup is largely in place, allowing for a 50% capacity increase in fermentation capacity without immediate expansion.
- A capacity expansion decision will be taken after September; some incremental capacity expansion may occur in a subsidiary.
- The new R&D facility is expected to be operational in the second half of the year, aiming to triple R&D capacity eventually.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Create a free account to keep reading this call
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Advanced Enzyme Technologies Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 203 | 167 | +21.6% | 172 | +18% |
| Operating profit (EBITDA) | 63 | 46 | +37% | 49 | +28.6% |
| Operating margin | 31% | 27% | +4 pp | 29% | +2 pp |
| Profit before tax | 60 | 43 | +39.5% | 58 | +3.4% |
| Net profit (PAT) | 45 | 27 | +66.7% | 43 | +4.7% |
| EPS (₹) | 3.84 | 2.37 | +62% | 3.80 | +1.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q4 FY26 results?
The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
